Specific Treatments for Major Acute Ischemic Stroke

Gary K. K. Lau; Sarah T. Pendlebury; Peter M. Rothwell

doi:10.1017/9781316161609.022

Chapter 21 - Specific Treatments for Major Acute Ischemic Stroke

from Section 4 - Treatment of Transient Ischemic Attack and Stroke

Published online by Cambridge University Press: 01 August 2018

Gary K. K. Lau ,

Sarah T. Pendlebury and

Peter M. Rothwell

Show author details

Gary K. K. Lau: Affiliation:
University of Oxford
Sarah T. Pendlebury: Affiliation:
University of Oxford
Peter M. Rothwell: Affiliation:
University of Oxford

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Transient Ischemic Attack and Stroke
Diagnosis, Investigation and Treatment
, pp. 307 - 327

DOI: https://doi.org/10.1017/9781316161609.022 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Albers, GW, von Kummer, R, Truelsen, T et al. (2015) Safety and efficacy of desmoteplase given 3–9 h after ischemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): A double-blind, randomized, placebo-controlled phase 3 trial. Lancet Neurology 14:575–584CrossRef Google Scholar

Albers, GW, Marks, MP, Kemp, S et al. (2018). Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. New England Journal of Medicine 378:708–718CrossRef Google Scholar PubMed

Anderson, CS, Robinson, T, Lindley, RI et al. (2016). Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. New England Journal of Medicine 374:2313–2323CrossRef Google Scholar PubMed

Berge, E (2007). Heparin for acute ischemic stroke: A never-ending story? Lancet Neurology 6:381–382Google Scholar

Berge, E, Cohen, G, Roaldsen, MB et al. (2016). Effects of alteplase on survival after ischemic stroke (IST-3): 3 year follow-up of a randomized, controlled, open-label trial. Lancet Neurology 15:1028–1034CrossRef Google Scholar

Berkhemer, OA, Fransen, PS, Beumer, D et al. (2015). A randomized trial of intraarterial treatment for acute ischemic stroke. New England Journal of Medicine 372:11–20CrossRef Google Scholar PubMed

Bernard, SAGT, Buist, MD, Jones, BM et al. (2002). Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. New England Journal of Medicine 346:557–563Google Scholar

Bhatia, R, Hill, MD, Shobha, N et al. (2010). Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: Real-world experience and a call for action. Stroke 41:2254–2258CrossRef Google Scholar

Broderick, JP, Palesch, YY, Demchuck, AM et al. (2013). Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. New England Journal of Medicine. 368:893–903Google Scholar

Brott, TG, Haley, EC Jr., Levy, DE et al. (1992). Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 23:632–640CrossRef Google Scholar

Campbell, BC, Mitchell, MJ, Kleinig, TJ et al. (2015). Endovascular therapy for ischemic stroke with perfusion-imaging selection. New England Journal of Medicine 372:1009–1018Google Scholar

Chinese Acute Stroke Trial (CAST) Collaborative Group (1997). CAST: Randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischemic stroke. Lancet 349:1641–1649CrossRef Google Scholar

Ciccone, A, Valvassori, L, Nichelatti, M et al. (2013). Endovascular treatment for acute ischemic stroke. New England Journal of Medicine 368:904–913Google Scholar

Clark, WM, Wissman, S, Albers, GW et al. (1999). Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for acute Noninterventional Therapy in Ischemic Stroke. JAMA 282:2019–2026Google Scholar

Collen, D. (1987) Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. Journal of Cellular Biochemistry 33:77–86Google Scholar

Connolly, SJ, Milling, TJ Jr., Eikelboom, JW et al. (2016). Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. New England Journal of Medicine 375:1131–1141Google Scholar

Davis, SM, Donnan, GA, Parsons, MW et al. (2008) Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): A placebo-controlled randomized trial. Lancet Neurology 7:299–309CrossRef Google Scholar

del Zoppo, GJ, Higashida, RT, Furlan, AJ et al. (1998). PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators Prolyse in Acute Cerebral Thromboembolism. Stroke 29:4–11CrossRef Google Scholar PubMed

Demaerschalk, BM, Kleindorfer, DO, Adeoye, OM et al. (2016). Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 47:581–641Google Scholar

Emberson, J, Lee, KR, Lyden, P et al. (2014). Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischemic stroke: A meta-analysis of individual patient data from randomized trials. Lancet 384:1929–1935Google Scholar

Fletcher, AP, Alkjaersig, N, Lewis, M et al. (1976). A pilot study of urokinase therapy in cerebral infarction. Stroke 7:135–142Google Scholar

Furlan, A, Higashida, R, Wechsler, L et al. (1999). Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism. Journal of the American Medical Association 282:2003–2011Google Scholar

Furlan, AJ, Eyding, D, Albers, GW et al. (2006). Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 37:1227–1231CrossRef Google Scholar PubMed

Goyal, M, Demchuk, AM, Menon, BK et al. (2015). Randomized assessment of rapid endovascular treatment of ischemic stroke. New England Journal of Medicine 372:1019–1030Google Scholar

Goyal, M, Menon, BK, van Zwam, WH et al. (2016). Endovascular thrombectomy after large-vessel ischemic stroke: A meta-analysis of individual patient data from five randomized trials. Lancet 387:1723–1731CrossRef Google Scholar

Gupta, R, Horev, A, Nguyen, T et al. (2013). Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes. Journal of NeuroInterventional Surgery 5:294–297Google Scholar

Hacke, W, Kaste, M, Fieschi, C et al. (1995). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Coorperative Acute Stroke Study (ECASS). JAMA 274:1017–1025Google Scholar

Hacke, W, Kaste, M, Fieschi, C et al. (1998). Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Second European–Australasian Acute Stroke Study Investigators. Lancet 352:1245–1251Google Scholar

Hacke, W, Albers, G, Al-Rawi, Y et al. (2005). The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36:66–73Google Scholar

Haley, EC Jr., Levy, DE, Brott, TG et al. (1992). Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 23:641–645CrossRef Google Scholar PubMed

Hankey, GJ, Norrving, B, Hacke, W et al. (2014). Management of acute stroke in patients taking novel oral anticoagulants. International Journal of Stroke 9:627–632Google Scholar

Hemmen, TM, Lyden, PD (2007). Induced hypothermia for acute stroke. Stroke 38:794–799CrossRef Google Scholar PubMed

Hypothermia After Cardiac Arrest Study Group (2002). Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. New England Journal of Medicine 346:549–556Google Scholar

International Stroke Trial Collaborative Group (1997). The International Stroke Trial (IST): A randomised trial of aspirin subcutaneous heparin both or neither among 19435 patients with acute ischemic stroke. Lancet 349:1569–1581CrossRef Google Scholar

IST-3 Collaborative Group (2012). The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischemic stroke [the third International Stroke Trial (IST-3)]: A randomized controlled trial. Lancet 379:2352–2363CrossRef Google Scholar

IST-3 Collaborative Group (2015). Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischemic stroke in the third International Stroke Trial (IST-3): Secondary analysis of a randomized controlled trial. Lancet Neurology 14:485–496Google Scholar

Jauch, EC, Saver, JL, Adams, HP et al. (2013). Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44:870–947CrossRef Google Scholar PubMed

Jovin, TG, Chamorro, A, Cobo, E et al. (2015). Thrombectomy within 8 hours after symptom onset in ischemic stroke. New England Journal of Medicine. 372:2296–2306Google Scholar

Kidwell, CS, Jahan, R, Gornbein, J et al. (2013). A trial of imaging selection and endovascular treatment for ischemic stroke. New England Journal of Medicine 368:914–923CrossRef Google Scholar PubMed

Krieger, DW, Yenari, MA (2004). Therapeutic hypothermia for acute ischemic stroke: What do laboratory studies teach us? Stroke 35:1482–1489Google Scholar

Lyden, PD, Madden, KP, Clark, WM et al. (1990). Incidence of cerebral hemorrhage after treatment with tissue plasminogen activator or streptokinase following embolic stroke in rabbits. Stroke 21:1589–1593Google Scholar

Ma, QF, Chu, CB, Song, HQ (2015). Intravenous versus intra-arterial thrombolysis in ischemic stroke: A systematic review and meta-analysis. PLoS One 10:e0116120Google Scholar

Menon, BK, Saver, JL, Prabhakaran, S et al. (2012). Risk score for intracranial hemorrhage in patients with acute ischemic stroke treated with intravenous tissue-type plasminogen activator. Stroke 43:2293–2299Google Scholar

Meyer, JS, Gilroy, J, Barnhart, MI et al. (1963). Therapeutic thrombolysis in cerebral thromboembolism. Double-blind evaluation of intravenous plasmin therapy in carotid and middle cerebral arterial occlusion. Neurology 13:927–937Google Scholar

Muir, KW (2001). Magnesium for neuroprotection in ischemic stroke: Rationale for use and evidence of effectiveness. CNS Drugs 15:921–930CrossRef Google Scholar

Multicenter Acute Stroke Trial – Europe Study Group (1996). Thrombolytic therapy with streptokinase in acute ischemic stroke. New England Journal of Medicine 335:145–150CrossRef Google Scholar

National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995). Tissue plasminogen activator for acute ischemic stroke. New England Journal of Medicine 333:1581–1588CrossRef Google Scholar

Nogueira, RG, Lutsep, HL, Gupta, R et al. (2012). Trevo versus Merci retrievers for thrombectomy revascularization of large vessel occlusion in acute ischemic stroke (TREVO 2): A randomized trial. Lancet 38:1231–1240Google Scholar

Nogueira, RG, Jadhav, AP, Haussen, DC et al. (2018). Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. New England Journal of Medicine 378:11–21Google Scholar

O’Donnell, MJ, Berge, E, Sandset, PM (2006). Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke 37:452–455Google Scholar

Parsons, M, Spratt, N, Bivard, A et al. (2012). A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. New England Journal of Medicine 366:1099–1107CrossRef Google Scholar PubMed

Pierot, L, Soize, S, Benaissa, A et al. (2015). Techniques for endovascular treatment of acute ischemic stroke: From intra-arterial fibrinolytics to stent-retrievers. Stroke 46:909–914Google Scholar

Pollack, CV Jr., Reilly, PA, Eikelboom, J et al. (2015). Idarucizumab for dabigatran reversal. New England Journal of Medicine 373:511–520CrossRef Google Scholar PubMed

Powers, WJ, Derdeyn, CP, Biller, J et al. (2015). 2015 American Heart Association/American Stroke Association focused updated of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 46:3020–3035CrossRef Google Scholar PubMed

Powers, WJ, Rabinstein, AA, Ackerson, T et al. (2018). Guidelines for the early management of patients with acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 49:e46–e110Google Scholar

Rothwell, PM, Algra, A, Chen, Z et al. (2016). Effects of aspirin on risk of severity of early recurrent stroke after transient ischemic attack and ischemic stroke: Time-course analysis of randomized trials. Lancet 388:365–375Google Scholar

Sandercock, P, Gubitz, G, Foley, P et al. (2003). Antiplatelet therapy for acute ischemic stroke. Cochrane Database of Systematic Reviews 2:CD000024Google Scholar

Saver, JL (2006). Time is brain-quantified. Stroke 37:263–266Google Scholar

Saver, JL, Jahan, R, Levy, EI et al. (2012). Solitaire flow restoration device versus the Merci Retriever in patients with acute ischemic stroke (SWIFT): A randomized, parallel-group, non-ineriority trial. Lancet 380:1241–1249CrossRef Google Scholar

Saver, JL, Goyal, M, Bonafe, A et al. (2015a). Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. New England Journal of Medicine 372:2285–2295Google Scholar

Saver, JL, Starkman, S, Eckstein, M et al. (2015b). Prehospital use of magnesium sulfate as neuroprotection in acute stroke. New England Journal of Medicine 372:528–536Google Scholar

Smith, WS, Sung, G, Starkman, S et al. (2005). Safety and efficacy of mechanical embolectomy in acute ischemic: Results of the MERCI trial. Stroke 35:1432–1438CrossRef Google Scholar

Smith, WS, Sung, G, Saver, J et al. (2008). Mechanical thrombectomy for acute ischemic stroke: Final results of the Multi MERCI trial. Stroke 39:1205–1212CrossRef Google Scholar PubMed

Sussman, BJ, Fitch, TS (1958). Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 167:1705–1709Google Scholar

Sutherland, BA, Minnerup, J, Balami, JS et al. (2012). Neuroprotection for ischemic stroke: Translation from the bench to the bedside. International Journal of Stroke 7:407–418CrossRef Google Scholar

Tanswell, P, Modi, N, Combs, D et al. (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy in acute myocardial infarction. Clinical Pharmacokinetics 41:1229Google Scholar

Tsivgoulis, G, Zand, R, Katsanos, AH et al. (2016). Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: A meta-analysis. JAMA Neurology 73:675–683Google Scholar

von Kummer, R, Mori, E, Truelsen, T et al. (2016). Desmoteplase 3 to 9 hours after major artery occlusion stroke: The DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke 47:2880–2887Google Scholar

Whiteley, WN, Emberson, JE, Lees, KR et al. (2016). Risk of intracerebral hemorrhage with alteplase after acute ischemic stroke: A secondary analysis of an individual patient data meta-analysis. Lancet Neurology 15:925–933Google Scholar

Wong, KS, Chen, C, Ng, PW et al. (2007). Low-molecular-weight heparin compared with aspirin for the treatment of acute ischemic stroke in Asian patients with large artery occlusive disease: A randomised study. Lancet Neurology 6:407–413CrossRef Google Scholar

Yamaguchi, T, Mori, E, Minematsu, K et al. (2006). Alteplase at 0.6mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke 37:1810–1815CrossRef Google Scholar

Yang, MH, Lin, HY, Fu, J et al. (2015). Decompressive hemicraniectomy in patients with malignant middle cerebral artery infarction: A systematic review and meta-analysis. The Surgeon 13:230–240Google Scholar

Zivin, JA, Fisher, M, DeGirolami, U et al. (1985). Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230:1289–1292Google Scholar

Book contents

Chapter 21 - Specific Treatments for Major Acute Ischemic Stroke

Summary

Access options

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive